Table 4 of Park, Mol Vis 2014; 20:1680-1694.


Table 4. Pharmacogenetic association with anti-vascular endothelial growth factor treatment outcome in neovascular age-related macular degeneration patients.

Outcome parameters Gene Variant Genotype (N)* N (%) or Mean* Genetic model OR (95% CI)** Uncorrected P - value Corrected P - value††
≥ 15-letter gain 12mo - - -   - - - -
  24mo VEGFA rs3025039 CC(219) / CT(124) / TT(23) 64(29.2) / 39(29.0) / 13(56.5) Recessive 4.57 (1.89-11.1) 0.0027 0.0434
BCVA change from baseline 12mo - - -   - - - -
  24mo - - -   - - - -
Dry status on OCT 12mo - - -   - - - -
  24mo - - -   - - - -
CSMT change from baseline 12mo ARMS2 rs10490924 TT(196) / TG(150) / GG(47) -62.9 / -62.4 / -118.6 (µm) Additive - 0.0141 0.2256
          Recessive - 0.004 0.0656
  HTRA1 rs11200638 AA(202) / AG(144) / GG(48) -63.0 / -62.4 / -115.7 (µm) Additive - 0.0141 0.2256
          Recessive - 0.0033 0.0528
24mo ARMS2 rs10490924 TT(183) / TG(139) / GG(44) -63.2 / -60.9 / -126.2 (µm) Additive   0.0384 0.6144
            Recessive - 0.0258 0.4128
    HTRA1 rs11200638 AA(188) / AG(133) / GG(45) -62.3 / -62.4 / -123.7 (µm) Additive - 0.0323 0.5168
            Recessive - 0.0293 0.4688
Number of injections 12mo ARMS2 rs10490924 TT(196) / TG(150) / GG(47) 6.8 / 6.8 / 6.1 Recessive - 0.0344 0.5504
    HTRA1 rs11200638 AA(202) / AG(144) / GG(48) 6.8 / 6.7 / 6.1 Recessive - 0.0304 0.4864
  24mo VEGFA rs3025039 CC(219) / CT(124) / TT(23) 10.7 / 10.4 / 9.0 Additive - 0.0286 0.4576
            Recessive - 0.015 0.2352
    ARMS2 rs10490924 TT(183) / TG(139) / GG(44) 10.5 / 10.9 / 9.4 Recessive - 0.0338 0.5408
    HTRA1 rs11200638 AA(188) / AG(133) / GG(45) 10.5 / 10.9 / 9.4 Recessive - 0.0275 0.4403